Table 4.

Summary of cefepime pharmacokinetic parameters for patients receiving CVVHDF

PatientDosing regimenCmax(μg/ml)Cmin(μg/ml)AUC0–24(μg · h/ml)t1/2 (h)V (liter/kg)CLSUFRa (ml/min)CRRT CLbSa b
ml/minml/min/kgml/minml/min/kg%CLS
61 g every 24 h44.85.8600.78.00.3038 ± 40.44 ± 0.0418 ± 225 ± 60.28 ± 0.0733 ± 100.73 ± 0.09
71 g every 24 h25.73.5344.98.20.5867 ± 50.81 ± 0.0620 ± 1023 ± 80.27 ± 0.1066 ± 180.65 ± 0.09
81 g every 12 h36.213.6581.88.30.3558 ± 10.49 ± 0.0114 ± 128 ± 10.24 ± 0.0248 ± 10.92 ± 0.02
92 g every 24 h72.910.4979.28.40.3226 ± 60.24 ± 0.0620 ± 447 ± 50.44 ± 0.0556 ± 140.73 ± 0.12
102 g every 24 h79.16.91,009.96.70.2136 ± 80.30 ± 0.0723 ± 745 ± 20.37 ± 0.0181 ± 190.93 ± 0.06
112 g every 24 h63.612.2890.99.90.2623 ± 20.17 ± 0.0113 ± 242 ± 10.31 ± 0.0153 ± 40.78 ± 0.07
122 g every 24 h90.820.41,306.810.90.3422 ± 10.27 ± 0.0214 ± 230 ± 10.36 ± 0.0176 ± 40.75 ± 0.05
Mean ± SD8.6 ± 1.40.34 ± 0.1247 ± 0.12c 0.46 ± 0.17c 17 ± 4c 26 ± 5c 0.25 ± 0.04c 59 ± 16c 0.78 ± 0.10c
  • a UFR, ultrafiltration rate.

  • b Values are means ± standard deviations calculated from parameter values determined during each of the four or five postdose sampling intervals for each patient: 1 to 2 h, 2 to 4 h, 4 to 8 h, 8 to 12 h, and 12 to 24 h (except with 12-h dosing interval regimens).

  • c Means ± standard deviations calculated from means of the four or five parameter values determined for each individual patient.